Neograft was founded to translate promising research in tissue engineering and regenerative medicine into real and useful solutions. Our first product, Angioshield, addresses inherent limits associated with using veins for coronary bypass surgery. The underlying science, discovered at the University of Pittsburgh, provides a foundation for many other new products.¹